Provided by Tiger Trade Technology Pte. Ltd.

Alterity Therapeutics Limited

3.34
-0.0845-2.47%
Volume:14.50K
Turnover:48.48K
Market Cap:60.46M
PE:-4.47
High:3.40
Open:3.39
Low:3.33
Close:3.42
52wk High:7.00
52wk Low:2.04
Shares:18.13M
Float Shares:12.46M
Volume Ratio:1.60
T/O Rate:0.12%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7470
EPS(LYR):-0.7470
ROE:-43.23%
ROA:-28.09%
PB:2.14
PE(LYR):-4.47

Loading ...

Company Profile

Company Name:
Alterity Therapeutics Limited
Exchange:
NASDAQ
Establishment Date:
1997
Employees:
9
Office Location:
350 Collins Street,Suite 4,Level 14,Melbourne,Victoria,Australia
Zip Code:
3000
Fax:
61 3 9349 4906
Introduction:
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.

Directors

Name
Position
Julian Barbaczy
Non-Executive Chair
Lawrence Gozlan
Director
Peter A. Marks
Director

Shareholders

Name
Position
David A. Stamler
Chief Executive Officer, Managing Director
Abby Macnish Niven
Company Secretary and Chief Financial Officer